IperionX Limited (Nasdaq: IPX; also listed in Australia) is developing titanium metal powder and related critical-minerals projects in the United States. Spruce Point Capital Management (@sprucepointcap), an activist short seller, published a forensic short report on November 12, 2025, and is still pressing the bear case. On September 30, 2026, after B Riley cut its IPX price target from $52 to $34 a share, Spruce Point wrote that the new target was "still far too optimistic" and stuck with a $1.50 to $3.00 range.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: IperionX Limited, IPX, Nasdaq (also ASX-listed).
- Situation type: Activist / forensic short on a pre-revenue or early-revenue materials story.
- The call: Spruce Point Capital (@sprucepointcap) is short IPX and reiterates a $1.50 to $3.00 price-target range.
- Price: IPX closed at $16.48 on October 9, 2026, after $18.30 on September 29, 2026 (the close before Spruce Point's September 30 post).
- Broker cut: B Riley reduced its IPX target from $52 to $34 a share, per Spruce Point's September 30, 2026 post.
- Spruce Point range: $1.50 to $3.00 a share, which Spruce says "may ultimately proven to be generous."
- Original report: Spruce Point's November 12, 2025 research page argued IPX traded at rich multiples versus book value and estimated 2026 revenue.
- Main risk for the short: A financed offtake, successful plant ramp, or lasting U.S. policy support that re-rates titanium developers higher.
Is IPX a good bet right now?
That depends on whether you believe IperionX is close to commercial titanium production with real customers, or a promotional story that still lacks offtake and financing.
Spruce Point's short says the latter. B Riley's cut from $52 to $34 still implies large upside from the mid-teens, so the Street and the short seller remain far apart.
Why are investors bearish on IperionX?
- Spruce Point's forensic list. In the September 30, 2026 post, Spruce Point said its earlier concerns had played out: financial-statement issues and a restatement; Titan Project challenges with "no offtake and no financing"; and "no revenue and operating cost bloat with accelerated cash burn."
- Valuation gap. Spruce Point's November 2025 report, as covered by outlets such as Hedge Fund Alpha, argued IPX traded at several times industry median book and revenue multiples for a company still proving the model.
- Target discipline. Even after B Riley's cut, Spruce Point refused to move off $1.50 to $3.00, calling higher targets still too optimistic for what it labels a promoter-driven story.
Who's making this call and why?
Spruce Point Capital (@sprucepointcap) is a forensic short seller that publishes research reports on companies it views as overvalued or promotional. The firm launched its IperionX work on November 12, 2025, and has kept posting updates as brokerage targets and company disclosures change.
Track record. In our tracking of Spruce Point's public calls, the firm is 11-6 (a .647 win rate) on 17 calls scored at 180 days against the S&P 500, with an average edge of +10.4 percentage points. Two newer calls are 2-0 on a provisional basis.
Other bearish context:
- U.S.-listed IPX shares fell after the original Spruce Point report, according to contemporaneous TradingView / Reuters coverage.
- B Riley's own target cut, even if still far above Spruce Point's range, is a partial concession that prior bull cases were too high.
Who disagrees?
- B Riley and other bulls still publish targets well above the market and far above Spruce Point's $1.50 to $3.00 band. A $34 target implies the broker still sees substantial upside from the mid-teens.
- Company narrative. IperionX markets U.S. titanium metal powder and critical-minerals optionality tied to domestic supply-chain policy. Believers argue that policy support and technical progress can justify premium multiples before revenue scales.
- Recent X search for balanced IPX debate was thin relative to promotional spam; readers should privilege SEC filings and Spruce Point's full PDF over social-media noise.
What are the key facts to verify?
- Spruce Point's IperionX research page and the November 12, 2025 report claims on financials, Titan Project status, revenue and cash burn.
- Whether IperionX has announced binding offtake agreements and project financing since those critiques.
- Current cash runway and operating losses in the latest ASX/Nasdaq filings.
- Any restatement history and auditor language.
- How IPX trades versus tangible book value and versus peer titanium or advanced-materials developers.
What would prove it right or wrong?
Signals the short is working:
- IPX stays without meaningful offtake or project finance while cash burn continues.
- Further brokerage target cuts or equity raises at dilutive prices.
- The stock moves toward Spruce Point's $1.50 to $3.00 range.
Signals it is failing:
- A financed commercial plant and contracted customers show up in filings.
- Revenue ramps and cash burn slows enough that mid-teens or higher prices look earned.
- Policy grants convert into durable funding without a toxic equity overhang.
This is journalism and commentary, not investment advice. We hold no position unless stated.